News Pfizer makes first-line case for Tukysa in breast cancer Pfizer's Tukysa looks poised to find a new role as first-line maintenance therapy for HER2-positive metastatic breast cancer.
News Roche delivers its data reveal for adjuvant giredestrant Roche reveals the data that has it excited about giredestrant in early-stage breast cancer, but how might it be positioned versus CDK4/6 inhibitors?
News Pfizer's $2bn+ obesity bet, and other weight-loss news Pfizer licenses another GLP-1 agonist, from YaoPharma, plus clinical updates from Zealand, Structure, Ascletis, Wave, and Boehringer Ingelheim.
News FDA set to raise bar for clinical trials of CAR-T therapies The FDA could make it harder for developers of CAR-T therapies to bring them to market by requiring full randomised controlled trials.
News Lab-in-a-loop specialist Relation attracts Novartis alliance UK-based AI and multi-omics company Relation Therapeutics will seek out targets for allergic diseases on behalf of Novartis in a $1.7bn-plus alliance.
News FDA backs first AI tool for use in trials, targeting MASH The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with MASH to help measure disease activity.
Digital AI, start-ups, and the future of human health: AION Labs’ Ma... In a new episode of the pharmaphorum podcast, Nicole Raleigh invites Mati Gill, CEO of AION Labs, back as guest.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
